MENLO PARK, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal quarter and the six months ended March 31, 2017, and reported on recent corporate developments. Corium’s fiscal year ends on September 30.
Recent Corporate Developments
* Pilot bioequivalence study for Corplex™ Donepezil complete; positive preliminary results reported — Corium has completed a three-way crossover pilot bioequivalence study for Corplex Donepezil, a once-weekly transdermal therapeutic for Alzheimer’s disease, comparing steady-state plasma concentrations achieved with the transdermal systems with those of daily oral Aricept® (donepezil hydrochloride) after five weeks of treatment. The combined preliminary results demonstrated that the Corplex Donepezil product candidate meets the primary statistical criteria for bioequivalence to oral Aricept, and provided clear guidance on the parameters for the company’s upcoming pivotal study. Corplex Donepezil was well tolerated with favorable adhesion, skin safety and gastrointestinal side effect profiles.
